CAS: 617-35-6; Ethyl 2-Oxopropanoate

相似化合物

99124-30-8 139507-52-1 116-09-6

上下游产品

CAS号97-64-3 乳酸乙酯 | CAS号7757-83-7 无水亚硫酸钠 | CAS号76339-59-8 ethyl 2-methyl-... | CAS号14273-06-4 1-Propynylethyl... | CAS号1099-45-2 乙基(三苯基膦)乙酸酯 | CAS号74-88-4 碘甲烷 | CAS号141-97-9 乙酰乙酸乙酯 | CAS号609-15-4 2-氯乙酰乙酸乙酯 | CAS号64-17-5 乙醇 | CAS号127-17-3 丙酮酸 | CAS号1114-98-3 Propanoic acid,... | CAS号108725-04-8 (3-ethoxy-3-oxo... | CAS号107018-39-3 ETHYL 2-HYDROXY... | CAS号101492-44-8 ethyl 2-(4-chlo... | CAS号104680-25-3 2-氨基噻吩-3,4-二甲酸二乙酯 | CAS号2524-52-9 2-吡啶甲酸乙酯 | CAS号1570-45-2 异烟酸乙酯 | CAS号41438-38-4 2,4-二乙基吡啶二羧酸 | CAS号687-47-8 (-)-乳酸乙酯 | CAS号7699-00-5 D-乳酸乙酯

甲基2-羟基-3-苯丙酸酯置于vpo/al2O3 Catalyst体系中,用 二甲基亚砜 作为反应溶剂,100.0 °C,1.0 Mpa 条件下,反应 4.0H,以90.2%的收率获得产物丙酮酸乙酯
参考文献:一种α-羟基羧酸酯选择性氧化制备α-氧代羧酸酯的方法
标题:一种α-羟基羧酸酯选择性氧化制备α-氧代羧酸酯的方法
摘要:一种α‑羟基羧酸酯选择性氧化制备α‑氧代羧酸酯的方法,涉及α‑氧代羧酸酯的制备领域,在液相溶剂中,以分子氧为氧源,以+4价v和+5价v复合的钒磷氧(Vpo)作催化剂,α‑羟基羧酸酯与分子氧反应选择性氧化制得α‑氧代羧酸酯;其中,所述钒磷氧(Vpo)催化剂是磷酸氧钒(Vopo4)(Vv)和焦磷酸氧钒((Vo)2P2O7)(Viv)复合的钒磷氧(Vpo)催化剂.钒磷氧(Vpo)催化剂为廉价的非贵金属催化剂,成本较低;反应可在常压下进行,对设备的要求较低;本发明实现α‑氧代羧酸酯的高收率(90%);催化剂经再活化后可重复利用.

专利信息

专利号:US-8138330-B2
优先权日:2006-09-11
标 题 :Process for the synthesis of oligonucleotides
发明人：LEUCK MICHAEL; WOLTER ANDREAS; STUMPE ALFRED
权利人:LEUCK MICHAEL; WOLTER ANDREAS; STUMPE ALFRED; SIGMA ALDRICH CO LLC
摘要:The present invention discloses novel methods for the synthesis of oligonucleotides with nucleoside phosphoramidites on solid supports. The methods comprise the stepwise chain assembly of oligonucleotides on supports with 5′-acyl phosphoramidites. The synthesis cycles consist of a front end deprotection step which is conducted with a solution of a primary amine or a phenolate, a phosphoramidite coupling step with a 5′-acyl nucleoside phosphoramidite in the presence of an activator, a phosphite oxidation step and an optional capping step. The novel methods improve the quality of synthetic oligonucleotides due to the irreversibility of the front end deprotection step, which prevents the formation of deletion sequences, and due to the avoidance of acidic reagents in the synthesis cycles, which prevent the formation of depurination side products. The invention further discloses novel nucleoside phosphoramidite compositions wherein the phosphoramidites carry acyl front end protective groups which are cleavable with primary amines or phenolates. The invention is applicable to the synthesis of oligodeoxyribonucleotides, oligoribonucleotides and oligonucleotides with modifications in their sugar or phosphate groups.

专利号:US-8153839-B2
优先权日:2005-09-14
标题:Method for synthesis of keto acids or amino acids by hydration of acetylene compound
发明人：OGO SEIJI; FUKUZUMI SHUN-ICHI
权利人:OGO SEIJI; FUKUZUMI SHUN-ICHI; JAPAN SCIENCE & TECH AGENCY
摘要:An object of the present invention is to provide a method for synthesis of keto acids by hydration of an acetylene compound (acetylene-carboxylic acids) under mild conditions free from harmful mercury catalysts and a method for synthesis of amino acids from acetylene-carboxylic acids in a single container (one-pot or tandem synthesis). In one embodiment of the method according to the present invention for synthesis of keto acids, acetylene-carboxylic acids is hydrated in the presence of a metal salt represented by General Formula (1), n nwhere M 1 represents an element in Group VIII, IX, or X of the periodic table, and X 1 , X 2 , or X 3 ligand represents halogen, H 2 O, or a solvent molecule, and k represents a valence of a cation species, and Y represents an anion species, and L represents a valence of the anion species, and each of K and L independently represents 1 or 2, and k×m=L×n.

专利号:US-9085538-B2
优先权日:2010-07-26
标题:Process for the preparation of key intermediates for the synthesis of statins or pharmaceutically acceptable salts thereof
发明人：CASAR ZDENKO; STERK DAMJAN; JUKIC MARKO
权利人:CASAR ZDENKO; STERK DAMJAN; JUKIC MARKO; LEK PHARMACEUTICALS
摘要:The invention relates to commercially viable process for the synthesis of key intermediates for the preparation of statins, in particular Rosuvastatin and Pitavastatin or respective pharmaceutically acceptable salts thereof. A new simple and short synthetic route for key intermediates is presented which benefits from the use of cheap and readily available starting materials, by which the conventionally most frequently used DIBAL-H as reducing agent can be avoided.

专利号:US-11311505-B2
优先权日:2017-02-24
标 题:Synergistic compositions to stimulate the synthesis of human lung and sinus surfactants to decrease coughing, increase FEV-1/FVC ratios, decrease lung fibrosis, by increasing apoptosis of myofibroblasts
发明人：MARTIN ALAIN
权利人:MARTIN ALAIN; CELLULAR SCIENCES INC
摘要:Methods for the treatment of patients with both Chronic Obstructive Pulmonary Disease (COPD) and pulmonary fibrosis, and of patients with idiopathic pulmonary fibrosis without COPD, by stimulating the synthesis of human and animal patient lung and sinus surfactants to increase lung functions, inhibiting fibrosis and reducing coughing and nasal erythema, include the following steps: A) analyzing and diagnosing a patient with a lung ailment selected from the group consisting of i) both COPD and pulmonary fibrosis; and ii) idiopathic pulmonary fibrosis without COPD; and, B) treating the patient to raise the patient's lung functions including FEV1/FVC ratio by contacting mammalian cells with a [therapeutically effective amount of a treatment] composition that includes: a) a pyruvate salt; b) a phosphate; c) a salt of calcium; and d) a salt of magnesium, in an aqueous carrier, containing no more than 2.2 grams of said pyruvate salt per liter.

专利号:US-10813893-B2
优先权日:2017-02-24
标 题:Compositions and methods for the treatment and prevention of chronic hypoxemia and dyspnea
发明人：MARTIN ALAIN
权利人:MARTIN ALAIN; CELLULAR SCIENCES INC
摘要:The present invention has shown that not all salts of pyruvic acid enhance lung functions or enhance the synthesis of lung surfactants and that certain salts of pyruvic acid with the correct concentrations of calcium, phosphate and magnesium, are synergistic in their ability to enhance the synthesis of lung surfactants that will enhance lung alveoli functions, while decreasing coughing and lung tightness, and increasing oxygen saturation values to prevent hypoxemia. This patent demonstrates that the sodium pyruvate formula with calcium, phosphate and magnesium was superior over standard sodium pyruvate formula in saline alone in the removal of mucus, reduction of lung or sinus infections, and in reducing drug side effects and congestion. The use of this formula clearly demonstrated that it can be used to produce better efficacy in patients with hypoxemia, with lung and sinus diseases including, asthma, COPD, cystic fibrosis, interstitial lung disease, allergic rhinitis, sinusitis, Alzheimer's, disease, Parkinson's disease, brain trauma, nicotine addiction, sleep apnea, autism, migraine headaches, sleep disorders, lung and sinus infections, cancer therapy with cancer drugs, nicotine addiction, and medications that cause a decrease in lung surfactants.

专利号:US-2008287407-A1
优先权日:2003-12-10
标题 :Nitric Oxide Releasing Pyruvate Compounds, Compositions and Methods of Use
发明人：GARVEY DAVID S; FANG XINQIN; KHANAPURE SUBHASH P; RANATUNGA RAMANI R; WEY SHIOW-JYI
权利人:NITROMED INC
摘要:The invention describes novel nitrosated and/or nitrosylated pyruvate compounds and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated and/or nitrosylated pyruvate compound, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The invention also provides novel compositions comprising at least one pyruvate compound and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one pyruvate compound, that is optionally nitrosated and/or nitrosylated, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. The invention also provides methods for treating diseases resulting from oxidative stress, diabetes, reperfusion injury following ischemia, preservation of tissues, organs, organ parts and/or limbs.